Cognition enhancing effect of the aqueous extract of Cinnamomum zeylanicum on non-transgenic Alzheimer's disease rat model: Biochemical, histological, and behavioural studies

Nutritional Neuroscience

Volumn 20, Issue 9, 2017, Pages 526-537

  Madhavadas, Sowmya ^a   Subramanian, Sarada ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Alzheimer's disease; Cholinesterase; Cinnamomum zeylanicum; Cognition; Glycogen synthase kinase 3 ; Hippocampus

Indexed keywords

ACETYLCHOLINESTERASE; CHOLESTEROL; CHOLINESTERASE; CINNAMON EXTRACT; ESTERASE; GLUCOSE; GLUTAMATE SODIUM; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; GSK3B PROTEIN, RAT; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PLANT EXTRACT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHROPOMETRY; AQUEOUS SOLUTION; ARTICLE; BARNES MAZE TASK; BEHAVIOR; BIOCHEMICAL ANALYSIS; CHOLINESTERASE INHIBITION; COGNITIVE DEFECT; CONTROLLED STUDY; DPPH RADICAL SCAVENGING ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; HISTOLOGY; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEARNING; MALE; NEWBORN; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; STEREOLOGY; ANIMAL; ANIMAL BEHAVIOR; BARK; CHEMICALLY INDUCED; CHEMISTRY; CINNAMOMUM ZEYLANICUM; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECT; EXPLORATORY BEHAVIOR; MAZE TEST; METABOLISM; NERVE CELL; ORGAN SIZE; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; ANIMALS; BEHAVIOR, ANIMAL; CINNAMOMUM ZEYLANICUM; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GLYCOGEN SYNTHASE KINASE 3 BETA; HIPPOCAMPUS; INSULIN RESISTANCE; MALE; MAZE LEARNING; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; ORGAN SIZE; PHOSPHORYLATION; PLANT BARK; PLANT EXTRACTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS, SPRAGUE-DAWLEY; SODIUM GLUTAMATE;

EID: 84978488622     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1080/1028415X.2016.1194593     Document Type: Article

References (55)

1. Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci 2013;33:6245–56. doi: 10.1523/JNEUROSCI.3672-12.2013
2. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17–24. doi: 10.1002/ana.410410106
3. Krasuski JS, Alexander GE, Horwitz B, Daly EM, Murphy DG, Rapoport SI, et al. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry 1998;43:60–68. doi: 10.1016/S0006-3223(97)00013-9
4. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002;58:1188–96. doi: 10.1212/WNL.58.8.1188
5. Gupta A, Bisht B, Dey CS., Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011;60:910–20. doi: 10.1016/j.neuropharm.2011.01.033
6. de la Monte SM, Wands JR., Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008;2:1101–13. doi: 10.1177/193229680800200619
7. Angelini, Rafacho A, Boschero AC, Bosqueiro JR., Involvement of the cholinergic pathway in glucocorticoid-induced hyperinsulinemia in rats. Diabetes Res Clin Pract 2010;87:184–91. doi: 10.1016/j.diabres.2009.11.008
8. Mathew M, Subramanian S., In vitro screening for anti-cholinesterase and antioxidant activity of methanolic extracts of Ayurvedic medicinal plants used for cognitive disorders. PLoS ONE 2014;9:e86804. doi: 10.1371/journal.pone.0086804
9. Madhavadas S, Subramanian S., Combination of Spirulina with glycyrrhizin prevents cognitive dysfunction in aged obese rats. Indian J Pharmacol 2015;47:39–44. doi: 10.4103/0253-7613.150327
10. Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA., Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 2003;26:3215–8. doi: 10.2337/diacare.26.12.3215
11. Lu Z, Jia Q, Wang R, Wu X, Wu Y, Huang C, et al. Hypoglycemic activities of A- and B-type procyanidin oligomer-rich extracts from different cinnamon barks. Phytomedicine 2011;18:298–302. doi: 10.1016/j.phymed.2010.08.008
12. Qin B, Panickar KS, Anderson RA., Cinnamon: potential role in the prevention of insulin resistance, metabolic syndrome, and type 2 diabetes. J Diabetes Sci Technol 2010;4:685–93. doi: 10.1177/193229681000400324
13. Couturier K, Batandier C, Awada M, Hininger-Favier I, Canini F, Anderson RA, et al. Cinnamon improves insulin sensitivity and alters the body composition in an animal model of the metabolic syndrome. Arch Biochem Biophys 2010;501:158–61. doi: 10.1016/j.abb.2010.05.032
14. Jain S, Sangma T, Shukla SK, Mediratta PK., Effect of Cinnamomum zeylanicum extract on scopolamine-induced cognitive impairment and oxidative stress in rats. Nutr Neurosci 2015;18:210–6. doi: 10.1179/1476830514Y.0000000113
15. Peterson DW, George RC, Scaramozzino F, Lapointe NE, Anderson RA, Graves DJ, et al. Cinnamon extract inhibits Tau aggregation associated with Alzheimer's disease in vitro. J Alzheimers Dis 2009;17:585–7. doi: 10.3233/JAD-2009-1083
16. Frydman-Marom A, Levin A, Farfara D, Benromano T, Scherzer-Attali R, Peled S, et al. Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. PLoS ONE 2011;6:e16564. doi: 10.1371/journal.pone.0016564
17. Jiao L, Zhang X, Huang L, Gong H, Cheng B, Sun Y, et al. Proanthocyanidins are the major anti-diabetic components of cinnamon water extract. Food Chem Toxicol 2013;56:398–405. doi: 10.1016/j.fct.2013.02.049
18. Madhavadas S, Kutty BM, Subramanian S., Amyloid beta lowering and cognition enhancing effects of ghrelin receptor analog [D-Lys (3)] GHRP-6 in rat model of obesity. Indian J Biochem Biophys 2014;51:257–62.
19. Mathew M, Subramanian S., In vitro evaluation of anti-Alzheimer effects of dry ginger (Zingiber officinale Roscoe) extract. Indian J Exp Biol 2014;52:606–12.
20. Ellman GL, Courtney KD, Andres V, Featherstone RM., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95. doi: 10.1016/0006-2952(61)90145-9
21. Paxinos G, Watson C., The rat nervous coordinates, the new coronal set. New York: Elsevier; 2004.
22. Madhavadas S, Kapgal VK, Kutty BM, Subramanian S., The neuroprotective effect of dark chocolate in monosodium glutamate-induced nontransgenic Alzheimer disease model rats: biochemical, behavioral, and histological studies. J Dietary Suppl 2016;13:449–60. doi: 10.3109/19390211.2015.1108946
23. Kjonigsen LJ, Leergaard TB, Witter MP, Bjaalie JG., Digital atlas of anatomical subdivisions and boundaries of the rat hippocampal region. Front Neuroinform 2011;5:2. doi: 10.3389/fninf.2011.00002
24. Gundersen HJ, Jensen EB, Kieu K, Nielsen J., The efficiency of systematic sampling in stereology–reconsidered. J Microsc 1999;193:199–211. doi: 10.1046/j.1365-2818.1999.00457.x
25. Hynd MR, Scott HL, Dodd PR., Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45:583–95. doi: 10.1016/j.neuint.2004.03.007
26. Grewer C, Gameiro A, Zhang Z, Tao Z, Braams S, Rauen T., Glutamate forward and reverse transport: from molecular mechanism to transporter-mediated release after ischemia. IUBMB Life 2008;60:609–19. doi: 10.1002/iub.98
27. Amin KA, Kamel HH, Abdeltawab MA., Protective effect of Garcinia against renal oxidative stress and biomarkers induced by high fat and sucrose diet. Lipids Health Dis 2011;10:6. doi: 10.1186/1476-511X-10-6
28. Geula C, Darvesh S., Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease. Drugs Today 2004;40:711–21. doi: 10.1358/dot.2004.40.8.850473
29. Luchsinger JA, Gustafson DR., Adiposity and Alzheimer's disease. Curr Opin Clin Nutr Metab Care 2009;12:15–21. doi: 10.1097/MCO.0b013e32831c8c71
30. Anderson RA, Broadhurst CL, Polansky MM, Schmidt WF, Khan A, Flanagan VP, et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem 2004;52:65–70. doi: 10.1021/jf034916b
31. Anderson RA, Qin B, Canini F, Poulet L, Roussel AM., Cinnamon counteracts the negative effects of a high fat/high fructose diet on behaviour, brain insulin signalling and Alzheimer-associated changes. PLoS ONE 2013;8:e83243. doi: 10.1371/journal.pone.0083243
32. Plotkin DA, Jarvik LF., Cholinergic dysfunction in Alzheimer disease: cause or effect? Prog Brain Res 1986;65:91–103. doi: 10.1016/S0079-6123(08)60644-5
33. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR., Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122–6. doi: 10.1002/ana.410100203
34. Samadi A, Valderas C, De los Rios C, Bastida A, Chioua M, Gonzalez-Lafuente L, et al. Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. Bioorg Med Chem 2011;19:122–33. doi: 10.1016/j.bmc.2010.11.040
35. Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, et al. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 1983;280:119–26. doi: 10.1016/0006-8993(83)91179-4
36. Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, et al. Regulation of mitochondrial pyruvate dehydrogenase activity by Tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci USA 1996;93:2719–23. doi: 10.1073/pnas.93.7.2719
37. Wang H, Wang R, Zhao Z, Ji Z, Xu S, Holscher C, et al. Coexistences of insulin signalling-related proteins and choline acetyltransferase in neurons. Brain Res 2009;1249:237–43. doi: 10.1016/j.brainres.2008.10.046
38. Jarvill-Taylor KJ, Anderson RA, Graves DJ., A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes. J Am Coll Nutr 2001;20:327–6. doi: 10.1080/07315724.2001.10719053
39. Gomez-Isla T, Price JL, McKeel JrDW, Morris JC, Growdon JH, Hyman BT., Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996;16:4491–500.
40. Forster MJ, Dubey A, Dawson KM, Stutts WA, Lal H, Sohal RS., Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Proc Natl Acad Sci 1996;93:4765–9. doi: 10.1073/pnas.93.10.4765
41. Squire LR., Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol Rev 2002;99:195–231. doi: 10.1037/0033-295X.99.2.195
42. Schuff N, Matsumoto S, Kmiecik J, Studholme C, Du A, Ezekiel F, et al. Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement 2009;5:454–62. doi: 10.1016/j.jalz.2009.04.1233
43. West MJ, Kawas CH, Stewart WF, Rudow GL, Troncoso JC., Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging 2004;25:1205–12. doi: 10.1016/j.neurobiolaging.2003.12.005
44. McEwen BS, Sapolsky RM., Stress and cognitive function. Curr Opin Neurobiol 1995;5:205–16. doi: 10.1016/0959-4388(95)80028-X
45. Guzmán-Vélez E, Feinstein JS, Tranel D., Feelings without memory in Alzheimer disease. Cogn Behav Neurol 2014;27:117–29. doi: 10.1097/WNN.0000000000000020
46. Hasselmo ME, McClelland JL., Neural models of memory. Curr Opin Neurobiol 1999;9:184–8. doi: 10.1016/S0959-4388(99)80025-7
47. Den Heijer T, Van Der Lijn F, Koudstaal PJ, Hofman A, Van Der Lugt A, Krestin GP, et al. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010;133:1163–72. doi: 10.1093/brain/awq048
48. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011;77:461–8. doi: 10.1212/WNL.0b013e318227b227
49. Zhu Y, Fotinos A, Mao LLJ, Atassi N, Zhou EW, Ahmad S, et al. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discov Today 2015;20:65–75. doi: 10.1016/j.drudis.2014.08.016
50. Smith AM, Pappalardo D, Chen W-JA., Estimation of neuronal numbers in rat hippocampus following neonatal amphetamine exposure: a stereology study. Neurotoxicol Teratol 2008;30:495–502. doi: 10.1016/j.ntt.2008.05.001
51. Fitting S, Booze RM, Hasselrot U, Mactutus CF., Dose-dependent long-term effects of Tat in the rat hippocampal formation: a design based stereological study. Hippocampus 2010;20:469–80.
52. Dokter M, von Bohlen und Halbach O., Neurogenesis within the adult hippocampus under physiological conditions and in depression. Neural Regen Res 2012;7:552–9.
53. Amrein I, Isler K, Lipp HP., Comparing adult hippocampal neurogenesis in mammalian species and orders: influence of chronological age and life history stage. Eur J Neurosci 2012;34:978–87. doi: 10.1111/j.1460-9568.2011.07804.x
54. von Bohlen und Halbach O., Involvement of BDNF in age-dependent alterations in the hippocampus. Front Aging Neurosci 2010;2:1–11.
55. Jana A, Modi KK, Roy A, Anderson JA, van Breemen RB, Pahan K., Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: therapeutic implications for neurodegenerative disorders. J Neuroimmune Pharmacol 2013;8:739–55. doi: 10.1007/s11481-013-9447-7